Zacks Investment Research lowered shares of ArQule (NASDAQ:ARQL) from a buy rating to a hold rating in a research report report published on Wednesday morning.

According to Zacks, “ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F-1 pathway, is partnered with Roche. “

A number of other brokerages have also commented on ARQL. ValuEngine upgraded ArQule from a strong sell rating to a sell rating in a report on Friday, November 17th. Needham & Company LLC upgraded ArQule from a hold rating to a buy rating in a report on Thursday, December 14th.

ArQule (NASDAQ ARQL) traded up $0.01 on Wednesday, reaching $1.83. The company had a trading volume of 198,307 shares, compared to its average volume of 293,177. ArQule has a 12-month low of $0.92 and a 12-month high of $1.98. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 2.33. The firm has a market cap of $159.41, a price-to-earnings ratio of -4.58 and a beta of 1.38.

ArQule (NASDAQ:ARQL) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. During the same period last year, the business earned ($0.08) earnings per share. research analysts expect that ArQule will post -0.39 EPS for the current year.

Hedge funds have recently modified their holdings of the company. Curbstone Financial Management Corp lifted its holdings in shares of ArQule by 100.0% during the third quarter. Curbstone Financial Management Corp now owns 104,572 shares of the biotechnology company’s stock worth $116,000 after buying an additional 52,286 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of ArQule by 0.9% during the second quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock worth $192,000 after buying an additional 1,385 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of ArQule during the third quarter worth approximately $2,220,000. Finally, First Eagle Investment Management LLC lifted its holdings in shares of ArQule by 5.0% during the third quarter. First Eagle Investment Management LLC now owns 12,438,996 shares of the biotechnology company’s stock worth $13,807,000 after buying an additional 591,421 shares during the last quarter. Institutional investors own 52.12% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “ArQule (ARQL) Stock Rating Lowered by Zacks Investment Research” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2018/01/14/arqule-arql-stock-rating-lowered-by-zacks-investment-research.html.

About ArQule

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Get a free copy of the Zacks research report on ArQule (ARQL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.